JILL HIPPENMEYER: Open Payments
NPI 1598354847 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$585 in 32 payments from 14 companies in 2025. Trend: 2023 $1,034 · 2024 $1,013 · 2025 $585
Food & beverage: $585
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 9 | $143 |
| Novo Nordisk Inc | 6 | $108 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $57 |
| ABBVIE INC. | 3 | $51 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $31 |
| PFIZER INC. | 1 | $30 |
| Verona Pharma, Inc. | 1 | $27 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Phathom Pharmaceuticals, Inc. | 1 | $25 |
| AstraZeneca Pharmaceuticals LP | 1 | $21 |
Products named: MOUNJARO, JARDIANCE, CAPLYTA, Wegovy, Ozempic, VRAYLAR, Ohtuvayre, Auvelity.
Industry payments across IN — which companies pay providers there.
